Clearmind Medicine Inc. (CMND)
- Previous Close
1.1900 - Open
1.1529 - Bid 0.8496 x 200
- Ask 1.4900 x 200
- Day's Range
1.1500 - 1.2000 - 52 Week Range
0.9210 - 23.7000 - Volume
22,710 - Avg. Volume
720,267 - Market Cap (intraday)
3.849M - Beta (5Y Monthly) -1.69
- PE Ratio (TTM)
-- - EPS (TTM)
-31.1700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
www.clearmindmedicine.comRecent News: CMND
Performance Overview: CMND
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CMND
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CMND
Valuation Measures
Market Cap
3.91M
Enterprise Value
-7.23k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.00
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.59%
Return on Equity (ttm)
-181.83%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.09M
Diluted EPS (ttm)
-31.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
9.37M
Total Debt/Equity (mrq)
1.87%
Levered Free Cash Flow (ttm)
1.27M